143 related articles for article (PubMed ID: 31741027)
1. Urinary biomarkers profiles in patients with neurogenic detrusor overactivity according to their neurological condition.
Richard C; Bendavid C; Hascoet J; Alimi Q; Khene ZE; Kerdraon J; Voiry C; Brochard C; Bouguen G; Siproudhis L; Manunta A; Gamé X; Peyronnet B
World J Urol; 2020 Sep; 38(9):2261-2268. PubMed ID: 31741027
[TBL] [Abstract][Full Text] [Related]
2. [Sensitivity and specificity of urinary and serum neurotrophins in the diagnosis of neurogenic detrusor overactivity in multiple sclerosis].
Bazhenov IV; Filippova ES; Bazarnyi VV; Sazonov SV; Volkova LI; Zaitseva LN
Urologiia; 2018 Jul; (3):44-48. PubMed ID: 30035417
[TBL] [Abstract][Full Text] [Related]
3. Urinary TIMP-2 and MMP-2 are significantly associated with poor bladder compliance in adult patients with spina bifida.
Peyronnet B; Richard C; Bendavid C; Naudet F; Hascoet J; Brochard C; Senal N; Jezequel M; Alimi Q; Khene ZE; Corlu A; Clément B; Siproudhis L; Bouguen G; Kerdraon J; Manunta A; Gamé X
Neurourol Urodyn; 2019 Nov; 38(8):2151-2158. PubMed ID: 31486131
[TBL] [Abstract][Full Text] [Related]
4. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of fesoterodine fumarate (8 mg) in neurogenic detrusor overactivity due to spinal cord lesion or multiple sclerosis: A prospective study.
Konstantinidis C; Samarinas M; Tzitzika M; Kratiras Z; Panagiotakopoulos G; Giannitsas K; Athanasopoulos A
Neurourol Urodyn; 2021 Nov; 40(8):2026-2033. PubMed ID: 34498773
[TBL] [Abstract][Full Text] [Related]
6. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
[TBL] [Abstract][Full Text] [Related]
7. [Guidelines on the urological management of the adult patient with spinal dysraphism (spina bifida)].
Manunta A; Peyronnet B; Olivari-Philiponnet C; Chartier-Kastler E; Saussine C; Phé V; Robain G; Denys P; Even A; Samson E; Grise P; Karsenty G; Hascoet J; Castel-Lacanal E; Charvier K; Guinet-Lacoste A; Chesnel C; Amarenco G; Haffner F; Haddad M; Le Normand L; Perrouin-Verbe MA; Perrouin-Verbe B; De Seze M; Ruffion A; Gamé X
Prog Urol; 2023 Mar; 33(4):178-197. PubMed ID: 36609138
[TBL] [Abstract][Full Text] [Related]
8. A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction.
Welk B; Hickling D; McKibbon M; Radomski S; Ethans K
Neurourol Urodyn; 2018 Nov; 37(8):2810-2817. PubMed ID: 30168626
[TBL] [Abstract][Full Text] [Related]
9. Urodynamic Differences between Complete and Incomplete Spinal Cord Injuries with Neurogenic Detrusor Overactivity.
García Fadrique G; Gallego D; Ordaz D; Climent L
Urol Int; 2020; 104(3-4):273-276. PubMed ID: 31461727
[TBL] [Abstract][Full Text] [Related]
10. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection.
Liu HT; Chancellor MB; Kuo HC
Eur Urol; 2009 Oct; 56(4):700-6. PubMed ID: 18472208
[TBL] [Abstract][Full Text] [Related]
11. The role of brain-derived neurotrophic factor (BDNF) in the development of neurogenic detrusor overactivity (NDO).
Frias B; Santos J; Morgado M; Sousa MM; Gray SM; McCloskey KD; Allen S; Cruz F; Cruz CD
J Neurosci; 2015 Feb; 35(5):2146-60. PubMed ID: 25653370
[TBL] [Abstract][Full Text] [Related]
12. Impact of intradetrusor botulinum toxin A injections on serum and urinary concentrations of nerve growth factor and brain-derived neurotrophic factor in patients with multiple sclerosis and neurogenic detrusor overactivity.
Philippova ES; Bazhenov IV; Ziryanov AV; Bazarny VV
Neurourol Urodyn; 2021 Jan; 40(1):95-101. PubMed ID: 33034916
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety of mirabegron in individuals treated for spinal cord injury- or multiple sclerosis-induced neurogenic detrusor overactivity.
Krhut J; Wohlfahrt P; Pudich J; Kufová E; Borovička V; Bílková K; Sýkora R; Mokriš J; Cífková R; Zachoval R; Zvara P
Int Urol Nephrol; 2021 Jun; 53(6):1089-1095. PubMed ID: 33417146
[TBL] [Abstract][Full Text] [Related]
14. The effect of intradetrusor botulinum neurotoxin type A on urinary NGF, TGF BETA-1, TIMP-2 levels in children with neurogenic detrusor overactivity due to myelodysplasia.
Top T; Sekerci CA; Isbilen-Basok B; Tanidir Y; Tinay I; Isman FK; Akbal C; Simsek F; Tarcan T
Neurourol Urodyn; 2017 Sep; 36(7):1896-1902. PubMed ID: 28090659
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
Mehta S; Hill D; McIntyre A; Foley N; Hsieh J; Ethans K; Teasell RW; Loh E; Welk B; Wolfe D
Arch Phys Med Rehabil; 2013 Aug; 94(8):1473-81. PubMed ID: 23632286
[TBL] [Abstract][Full Text] [Related]
16. Molecular Mechanism Operating in Animal Models of Neurogenic Detrusor Overactivity: A Systematic Review Focusing on Bladder Dysfunction of Neurogenic Origin.
Ferreira A; Nascimento D; Cruz CD
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834694
[TBL] [Abstract][Full Text] [Related]
17. TASCI-transcutaneous tibial nerve stimulation in patients with acute spinal cord injury to prevent neurogenic detrusor overactivity: protocol for a nationwide, randomised, sham-controlled, double-blind clinical trial.
Birkhäuser V; Liechti MD; Anderson CE; Bachmann LM; Baumann S; Baumberger M; Birder LA; Botter SM; Büeler S; Cruz CD; David G; Freund P; Friedl S; Gross O; Hund-Georgiadis M; Husmann K; Jordan X; Koschorke M; Leitner L; Luca E; Mehnert U; Möhr S; Mohammadzada F; Monastyrskaya K; Pfender N; Pohl D; Sadri H; Sartori AM; Schubert M; Sprengel K; Stalder SA; Stoyanov J; Stress C; Tatu A; Tawadros C; van der Lely S; Wöllner J; Zubler V; Curt A; Pannek J; Brinkhof MWG; Kessler TM
BMJ Open; 2020 Aug; 10(8):e039164. PubMed ID: 32792454
[TBL] [Abstract][Full Text] [Related]
18. Comparison of neurogenic lower urinary tract dysfunctions in open versus closed spinal dysraphism: A prospective cross-sectional study of 318 patients.
Peyronnet B; Brochard C; Jezequel M; Hascoet J; Alimi Q; Senal N; Carsin-Nicole B; Riffaud L; Le Reste PJ; Bonan I; Olivari-Philiponnet C; Siproudhis L; Kerdraon J; Game X; Manunta A
Neurourol Urodyn; 2018 Nov; 37(8):2818-2826. PubMed ID: 30070396
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life and economic impact of urinary incontinence due to detrusor overactivity associated with a neurologic condition: a systematic review.
Tapia CI; Khalaf K; Berenson K; Globe D; Chancellor M; Carr LK
Health Qual Life Outcomes; 2013 Jan; 11():13. PubMed ID: 23369111
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
